検索
Regenxbio Inc
RGNXウォッチリストに追加
13.280USD
+0.190+1.45%
終値 07/02, 13:00（ET）15分遅れの株価
686.54M時価総額
損失額直近12ヶ月PER
詳細情報 Regenxbio Inc 企業名
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Regenxbio Incの企業情報
企業コードRGNX
会社名Regenxbio Inc
上場日Sep 17, 2015
最高経営責任者「CEO」Simpson (Curran M)
従業員数353
証券種類Ordinary Share
決算期末Sep 17
本社所在地9804 Medical Center Drive
都市ROCKVILLE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号20850
電話番号12405528181
ウェブサイトhttps://regenxbio.com/
企業コードRGNX
上場日Sep 17, 2015
最高経営責任者「CEO」Simpson (Curran M)
Regenxbio Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
45.81K
-165.45%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
31.87K
+30.77%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
28.86K
+33.98%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
28.86K
+33.98%
Mr. Kenneth T. (Ken) Mills
Mr. Kenneth T. (Ken) Mills
Chairman of the Board
Chairman of the Board
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
45.81K
-165.45%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
31.87K
+30.77%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
28.86K
+33.98%
よくある質問
Regenxbio Incの上位5名の株主は誰ですか？
Regenxbio Incの上位5名の株主は以下のとおりです。Mr. Mitchell Chan
Regenxbio Inc（RGNX）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Regenxbio Incの株式を保有している機関は410社あり、保有株式の総市場価値は約45.28Mで、全体の87.72%を占めています。2025Q4と比較して、機関の持ち株は-3475301.00増加しています。